… , NOACs) are overall safe and effective alternatives to warfarin treatment. We … non-vitamin
K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) in relation to patient char…

… , rivaroxaban, and warfarin had event rates of 3.3%, 3.5%, and 3.7%, respectively. In the
comparison between a non-vitamin K antagonist oral anticoagulant and warfarin in the inverse …

… of Cardiology) using the terms novel oral anticoagulants or non‐vitamin K antagonist oral
anticoagulants or direct oral anticoagulants or dabigatran or rivaroxaban or apixaban or …

… the phase III trials comparing the non–vitamin K antagonist oral anticoagulants (NOACs)
with warfarin (6–9). One phase II trial testing the direct thrombin inhibitor dabigatran etexilate in …

… if patients are treated with prophylactic oral anticoagulation (OAC). For decades, vitamin K
antagonists (VKAs) were the only option for OAC treatment until non-VKA oral anticoagulants (…

… Aims Non-vitamin K antagonist oral anticoagulants (NOACs) were in pivotal randomised …
warfarin for stroke prevention in atrial fibrillation, but time in therapeutic range (TTR) for warfarin …

… Since 2009, several new anticoagulants have been … in patients with non-valvular atrial
fibrillation (AF) [1], [2], [3], [4]. These drugs include non-vitamin K antagonist oral anticoagulants (…

… and vitamin K antagonists (VKAs) for stroke prevention in elderly patients with AF. For …
non-vitamin K antagonist oral anticoagulants’, ‘direct oral anticoagulant’, ‘new oral anticoagulant…

… Bleeding NOAC Warfarin Non-vitamin K antagonist oral anticoagulants (NOACs) are approved
for prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). These …

… Therefore, they are more often denied effective anticoagulants. Because non-vitamin K
antagonist oral anticoagulants (NOACs) have fewer drug interactions and require no need for …